UK markets open in 6 hours 1 minute
NIKKEI 225
38,700.01 -246.92 (-0.63%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.30 -0.60 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,179.98 -781.08 (-1.40%)
Celldex Therapeutics, Inc. (CLDX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 2.49B |
| Enterprise value | 1.67B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 319.33 |
| Price/book (mrq) | 2.97 |
| Enterprise value/revenue | 274.44 |
| Enterprise value/EBITDA | -17.34 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.60 |
| 52-week change 3 | 15.30% |
| S&P500 52-week change 3 | 28.04% |
| 52-week high 3 | 53.18 |
| 52-week low 3 | 22.11 |
| 50-day moving average 3 | 40.32 |
| 200-day moving average 3 | 34.63 |
Share statistics
| Avg vol (3-month) 3 | 909.7k |
| Avg vol (10-day) 3 | 565.99k |
| Shares outstanding 5 | 65.91M |
| Implied shares outstanding 6 | 66.05M |
| Float 8 | 65.73M |
| % held by insiders 1 | 0.34% |
| % held by institutions 1 | 107.35% |
| Shares short (30 Apr 2024) 4 | 6.99M |
| Short ratio (30 Apr 2024) 4 | 11.33 |
| Short % of float (30 Apr 2024) 4 | 12.28% |
| Short % of shares outstanding (30 Apr 2024) 4 | 10.60% |
| Shares short (prior month 28 Mar 2024) 4 | 6.56M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 11 Feb 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:15 |
| Last split date 3 | 11 Feb 2019 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -26,030.77% |
Management effectiveness
| Return on assets (ttm) | -15.73% |
| Return on equity (ttm) | -25.39% |
Income statement
| Revenue (ttm) | 6.07M |
| Revenue per share (ttm) | 0.12 |
| Quarterly revenue growth (yoy) | -83.90% |
| Gross profit (ttm) | N/A |
| EBITDA | -147.12M |
| Net income avi to common (ttm) | -144.88M |
| Diluted EPS (ttm) | -2.86 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 823.85M |
| Total cash per share (mrq) | 12.5 |
| Total debt (mrq) | 2.11M |
| Total debt/equity (mrq) | 0.25% |
| Current ratio (mrq) | 31.77 |
| Book value per share (mrq) | 12.72 |
Cash flow statement
| Operating cash flow (ttm) | -119.36M |
| Levered free cash flow (ttm) | -54.98M |
© 2024 Yahoo. All rights reserved.